{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-038002","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.170751+00:00","generated_at":"2026-06-12T08:59:18.903306+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sana Q2 net loss $114M ($0.59/shr); cash $325.9M; SC291 enrollment ongoing, data expected H2 2023","bullets":["Net loss of $114M in Q2 2023 vs $72.5M in Q2 2022; six-month net loss $196.1M.","Cash, cash equivalents, and marketable securities $325.9M as of June 30, 2023, expected to fund operations into 2025.","Enrolling patients in ARDENT Phase 1 trial for SC291 (CD19 CAR T) in B-cell malignancies; initial clinical data expected in H2 2023.","Plan to file IND for SC262 and SG299 in hematologic cancers and SC451 (islet cell) in type 1 diabetes in 2024.","Appointed Doug Williams as President of R&D and Gary Meininger as CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-038002","json":"https://secwatch.observer/filing/0000950170-23-038002.json","markdown":"https://secwatch.observer/filing/0000950170-23-038002.md","text":"https://secwatch.observer/filing/0000950170-23-038002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000095017023038002/0000950170-23-038002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000095017023038002/sana-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:59:18.903306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ee4204560df199ccb6787360001cfd9a4d18ad9","claim":"Sana Biotechnology, Inc. reported financial results for the quarter and year ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000095017023038002/0000950170-23-038002-index.htm","confidence":0.6,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}